Edesa Biotech, Inc. (EDSA) will be presenting phase 3 study results of its drug candidate Paridiprubart, as a treatment for acute respiratory distress syndrome, at the American Thoracic Society (ATS) 2026 International Conference in May of this year.
Acute Respiratory Distress Syndrome (ARDS) occurs when the lungs become severely inflamed, making it hard for oxygen to reach the blood. It can be triggered by severe infections like pneumonia, inhaling smoke or chemicals, sepsis (a body-wide infection), chest injuries, and other serious illnesses. ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million patients globally each year.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.